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Hilde Both1, Marie-Louise Essink-Bot2, Jan Busschbach3 and Tamar Nijsten1
The measurement of health-related quality of life
(HRQOL) is increasingly important in patients with
skin diseases. Despite the availability of a variety of
instruments and new psychometric techniques, there
is no consensus as to which HRQOL instruments are
to be preferred in dermatology. The objective of this
review is to evaluate the generic HRQOL measures
(i.e., health profiles) that have been used in dermatol-
ogy (Short-Form-36 (SF-36) and -12, NHP, SIP, World
Health Organization Quality of Life (WHOQOL)-100
and -BREF) and all dermatology-specific HRQOL
measures (Dermatology Life Questionnaire Index,
Skindex-29, -16, and -17, Dermatology Quality of Life
Scales, and Dermatology-Specific Quality of Life).
Criteria for evaluation were adapted from existing
guidelines and included conceptual and measure-
ment model, reliability, validity, responsiveness, item
functioning, meaning of scores, administrative bur-
den, respondent burden, the availability of alternative
forms, and of cultural and language adaptations.
Furthermore, an overview of skin diseases in which
the included HRQOL tools have been used is
presented. Although the selection of the appropriate
HRQOL instrument remains a trade-off between
various psychometric properties and research objec-
tives, for now, we recommend the combination of SF-
36 and Skindex-29 as the instruments of choice in
dermatology. Promising new instruments for future
research are the WHOQOL and the Skindex-17.
Journal of Investigative Dermatology (2007) 127, 2726–2739;
doi:10.1038/sj.jid.5701142; published online 8 November 2007
INTRODUCTION
The World Health Organization (WHO) defined quality of
life (QOL) as ‘‘the individuals’ perception of their position in
life, in the context of the cultural and value systems in which
they live and in relation to their goals, expectations, standards
and concerns’’. QOL is multidimensional and is determined
by health and multiple non-medical aspects such as socio-
economic status, marital status, professional career, person-
ality, happiness, ambition, expectations, and religious
experience. In medicine, QOL assessments focus on health-
related (HR)QOL because of its focus. HRQOL measures
include the physical, psychological, and social health
domains both in a subjective and objective manner (e.g.,
work impairment is relatively objective measure of the social
domain compared to personal relations; Testa and Simonson,
1996; Muldoon et al., 1998). Especially in chronic non-life-
threatening diseases such as skin diseases, HRQOL has
become increasingly important in the assessment of disease
severity, the evaluation of interventions, and allocation of
resources.
In dermatology, HRQOL can be assessed with generic
instruments (i.e., applicable in a broad range of conditions
allowing for comparisons between diseases), dermatology-
specific instruments (i.e., applicable in all skin diseases and
allowing for comparisons between skin diseases) and condi-
tion-specific instruments (i.e., use is restricted to a specific
skin disease and only comparisons between patient groups
with the same skin condition are possible). More specific
HRQOL tools are clinically sensible, often have a good
conceptual validity, and may be more responsive than
generic instruments (Wiebe et al., 2003). Most of the generic
instruments have been developed for use in conjunction with
condition-specific instruments. Among the generic HRQOL
measures, there is a distinction between health profiles and
preference-based measures. Health profiles assess different
domains of HRQOL resulting in scores for each of these
domains (some health profiles also provide a composite
score). The preference-based tools provide a single score (i.e.,
a health index), usually between 0 and 1, that is based on
empirically measured preference weights (Coons et al.,
2000). Preference-based measures are especially designed
for use in health economics.
The objective of this review is to grade several psycho-
metric characteristics of the most commonly used generic
health profiles and dermatology-specific HRQOL instruments
to provide an overview of the advantages and limitations of
each of these tools. It may assist researchers to choose the
most appropriate HRQOL instruments for their studies and to
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identify important research questions in the field of derma-
tology and HRQOL measurement.
DISCUSSION
Instrument of choice
Making an informed decision about the choice of a HRQOL
measure or combination of measures is a trade-off between
the pros and cons of the available instruments (preferable
tested in dermatology patients), the objective of the study and
the disease under investigation. Table 1 enables researchers
in dermatological HRQOL research to make an evidence-
based choice for selecting an appropriate measure with the
best properties in consideration of its application. Of the
psychometric properties, conceptual validity of an HRQOL
instrument is crucial in every study design, reliability in
particular in cross-sectional studies and responsiveness in
clinical trials. For most applications, the Short-Form-36 (SF-
36) is the reference measure and the WHOQOL is promising
generic (HR)QOL measure (Table 2). Of the dermatology-
specific HRQOL tools, the Skindex-29 is the most optimal
available instrument, but it is challenged by its brief versions
such as the Skindex-17. Adding a generic to a dermatology-
specific health profile is generally recommended and is
especially indicated if there is a need to compare HRQOL
across diseases like in burden of disease studies, measure
individuals’ health status in generic terms, and in situations
where the skin disease has a substantial generic HRQOL
impact beyond the disease-specific impact. In health
economic analyses such as cost-effectiveness analyses, the
EQ-5D is the measure of choice (EuroQoL group, 1990;
Brooks, 1996; www.euroqol.org) and the SF-6D may be a
promising alternative (Brazier et al., 1998, 2002).
We have tried to minimize bias in the grading of the
HRQOL instruments by using widely accepted criteria and
reaching consensus by three HRQOL experts. We acknowl-
edge that apart from quality, the quantity of available studies
is likely to affect the grading of the included instruments. This
implies that newer instruments are likely to be graded lower
on several criteria than older instruments and that very
commonly used measure may score better or worse (SF-36
and Dermatology Life Questionnaire Index (DLQI), respec-
tively) than those less commonly used. An overall quality
score, as is often done in systematic reviews, was not given
because it assumes that the contribution of the different
measurement properties to the overall quality is known and
that these properties are equally important.
Further research
The increasing importance of HRQOL in clinical practice
(i.e., included in reimbursement criteria of the biologicals for
psoriasis), clinical trials (i.e., important end points), and
resource allocation (i.e., cross-sectional, comparative, and
pharmacoeconomic studies) warrants the use of state-of-the-
art generic and specific instruments. This increased impor-
tance of HRQOL measures emphasizes the need for more
methodological studies about HRQOL in dermatology.
A prospective, international comparative study of several
generic instruments (including at least the SF-36, WHOQOL,
and EQ-5D) may show where and to what extent the most
optimal generic HRQOL instrument fail to assess pivotal
dermatology-specific HRQOL information, which should be
obtained by a more specific tool. Because each of the existing
dermatology-specific instruments has conceptual limitations
and/or suboptimal or unknown psychometric properties an
existing instrument such as the Skindex (or its short versions)
should be studied and refined or a tool should be developed
ex novo. It may also be worthwhile to obtain preferences of
the possible health states of this dermatology-specific
HRQOL by the general population so that it can be used to
calculate quality-adjusted life years.
Although it is a dilemma how to judge, select, and
incorporate new insights and techniques in current HRQOL
research, item response theory (IRT) models are now
considered standard in the psychometric community, espe-
cially in the evaluation of instruments’ structure (graded ‘‘A’’;
Table 3; McHorney, 1997). In contrast to the generic tools,
relatively few studies have used IRT in existing dermatology-
specific HRQOL instruments (Mazzotti et al., 2005; Nijsten
et al., 2006a, b, 2007), but it has been used in the
development of a psoriasis and atopic dermatitis-specific
HRQOL instrument (McKenna et al., 2003; Whalley et al.,
2004). Because HRQOL instruments are used in populations
that vary in demographically, cultural background, and/or
disease characteristics, it is pivotal that responses to items
and scales should not be affected by these external factors,
except for the differences the tool intends to measure (i.e.,
HRQOL impairment; Angoff, 1993; McHorney and Fleish-
man, 2006). However, little evidence exists about the item
bias across important variables such as gender, age, cultural
background, diagnosis, and clinical disease severity of the
dermatology-specific instruments, except for the Skindex-17
(Nijsten et al., 2006a, b, 2007). It would also be very
interesting to explore further the effect of comorbidity on
patients’ skin-related QOL (Unaeze et al., 2006; Chen et al.,
in press).
Conclusion
For now, the SF-36 and the Skindex are the HRQOL
instruments of choice and promising ‘‘runnerup’’ measures
are the WHOQOL and the Skindex-17. However, additional
methodological studies are needed to compare and improve
our understanding of these instruments in a heterogeneous
population to reach a consensus of HRQOL measurement in
dermatology.
MATERIALS AND METHODS
Multiple tools were identified based on several recent reviews on
generic and/or dermatology-specific HRQOL instruments (Finlay,
1997; Ashcroft et al., 1998; Coons et al., 2000; Halioua et al., 2000;
De Korte et al., 2002; Bennett et al., 2003; Haywood et al., 2005;
Nemeth, 2006). We consulted existing reviews and we system-
atically searched Pubmed for publications of the instruments’
characteristics by entering the ‘‘MeSH’’ terms ‘‘Quality of Life’’,
‘‘Dermatology’’, and ‘‘Skin’’ in combination with the full and the
abbreviated name of each of the identified instruments. Also,
reference lists of all papers obtained were hand searched to identify
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additional studies of interest. Generic HRQOL measures were
included if they were designed to assess health profiles and used
in one or more dermatological studies. All dermatology-specific
HRQOL instruments were included, except those instruments that
were developed with the intention to be used only in specific
countries such as Germany, French, and Turkey (Grob et al., 1999;
Schafer et al., 2001; Gurel et al., 2005). HRQOL measures that
focused on only one specific skin condition were not included in this
review.
For each criterion, the selected HRQOL instruments were graded
simply from A (excellent track record), C (substantial inadequacy or
not reported), and B somewhere in between. The evaluation criteria
included conceptual and measurement model, reliability, validity,
responsiveness, item bias, meaning of scores, administrative burden,
respondent burden, and the availability of alternative forms, and of
cultural and language adaptations (Table 3). This set of criteria was
adapted from the Medical Outcomes Trust (Lohr et al., 1996;
Andresen, 2000). The criteria on validation in dermatology patients,
interpretability of scores and test–retest reliability were added
(Guyatt et al., 2002; Terwee et al., 2007). The grading of the
HRQOL measures was performed by TN, MLEB, and JB until
consensus was reached. If uncertainty remained about the appro-
priate grading, we selected the most favorable option. Because of a
limited number of psychometric evaluations of generic HRQOL
instruments in dermatology patients, the presented grades were
based on other (diseased) populations. Because psychometric
properties depend on the population studied, we discussed the
psychometric properties of each measure reported in dermatology
patients separately.
Generic HRQOL instruments (health profiles)
Medical Outcome Study Short Form. The SF-36 is a health
survey questionnaire designed for use in epidemiological and
clinical research and practice by American social scientists working
Table 1. Global evaluation of generic and dermatology-specific HRQOL instruments
Generic HRQOL instruments
Dermatology-specific HRQOL instrumentsHealth profiles
Characteristics SF-36 NHP SIP WHOQOL DLQI Skindex-29 Skindex-16 Skindex-17 DSQL DQOLS
Validity
Conceptual A B B A B A A A B A
Construct A A A A A A A A B B
Convergent A A A A A A A A B C
Interpretability
Norms A B C B C C C C C C
2Categorization B C C C A B C B C C
MCID A C C C B C C C C C
Dermatology patients
Development A C C B B A A A C B
Testing — — — — A A B C C B
Measurement model B B B A B A A A C A
Reliability
Internal consistency A B A B A A A A A A
Retest reliability A1 A A A B2 A2 B2 C2 C2 B2
Structure B3 B C A C B B A B B
Responsiveness A B B A A A A C B C
Item bias A B C B C B C A C C
Cultural issues
Translations A B B A B B C B C C
Cultural equivalence A B C A C C C B C C
Respondent burden B A C C A B A A B B
Administrative burden A A C A A A A A B A
Alternative forms A B B B C C C C C C
DLQI, Dermatology Life Questionnaire Index; DSQL, Dermatology-Specific Quality of Life; DQOLS, Dermatology Quality of Life Scales; HRQOL, health-
related quality of life; MCID, minimal clinically important difference; NHP, Nottingham Health Profile; SF-36, Short-Form-36; SIP, Sickness Impact Profile;
WHOQOL, World Health Organization Quality of Life. — not applicable.
1Most authors report an good retest reliability (Coons et al. (2000); Haywood et al. (2005)), but this is debated by some authors (Hunt and McKenna (1993);
Gompertz et al. (1992)).
2Retest reliability expressed as correlation coefficients, which were all good to excellent, but not as k coefficients.
3Item response theory models only confirmed the unidimensionality of the physical functioning scale but not of other scales and components.
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for a health insurance survey (Brazier et al., 1992; Ware and
Sherbourne, 1992; Ware et al., 1993; Stewart et al., 1988; www.
sf-36.org). The items represent professionals’ assumptions about
issues relevant to health status and relate to the previous 4 weeks,
except the item about general health (last year). An ‘‘acute version’’
of the SF-36 makes use of a reference period for HRQOL of ‘‘last
week’’. The items are assigned to eight scales each aggregating 2–10
items, except a single item on perceived change in health (Table 4).
The SF-36 is the only instrument assessing a notion of positive health
(‘‘full of life’’), which may make it a sensitive instrument in the better
ranges of HRQOL. Factor analysis of the SF-36 showed a two-factor
model with physical and mental component (abbreviated to PCS and
MCS, respectively) with separate summary scores (Ware et al., 1993;
Essink-Bot et al., 1997). IRT models demonstrated the unidimension-
ality of the physical functioning scale (Haley et al., 1994; van der
Heijden et al., 2003), but not of the other scales. The SF-36 scored
well for most of the other psychometric features reviewed (Tables 1
and 2), except that half the scales suffer from suboptimal response
distributions (i.e., floor effect in very sick patients and some ceiling
effect in general population) The test–retest reliability was below
0.70 for three scales (Brazier et al., 1992; Gompertz et al., 1992;
Hunt and McKenna, 1993; McHorney et al., 1994). It takes about
7–10 minutes to complete the questionnaire and multiple adminis-
tration modes are available (www.sf-36.org). The SF-36 is available
in more than 50 different languages and has been tested extensively
for cultural equivalence (Anderson et al., 1996; Wagner et al.,
1998; www.sf-36.org). Norms have been calculated for the
general US population and representative samples of the United
Kingdom and other European countries. Although it has been
assumed that the minimal clinically important difference (MCID) of
the SF-36 scales was about 3–5 points (Stewart et al., 1989), the
MCID may vary more between scales and diseases (Wyrwich et al.,
2005) and the exact MCID of the eight scales in dermatology patients
is unknown.
The SF-36 has been widely used in dermatology with different
objectives. For instance, it has been used as a reference HRQOL
measurement in validation studies of dermatology-specific instru-
ments such as the DLQI and Skindex (Chren et al., 1997a; Abeni
et al., 2002; Lewis and Finlay, 2004). The SF-36 has also been used
in cross-sectional studies (Table 5), epidemiological surveys
(Bingefors et al., 2002), and in clinical psoriasis trails (Reich et al.,
2006; Shikiar et al., 2006). A systematic review of the HRQOL tools
in psoriasis concluded that the SF-36 is the generic instrument of
choice (De Korte et al., 2002). The PCS and to a much lesser extent
the MCS of the SF-36 correlated well with the DLQI (Wallenhammar
et al., 2004; Sampogna et al., 2004a; Shikiar et al., 2006). Several
psychometric properties of the SF-36 have been studied in detail
using data from an adalimumab trial in psoriasis patients (Shikiar
et al., 2006). The bodily pain and social functioning scales
correlated well with the DLQI, EQ-5D, and clinical end points,
and these scales were most responsive to change after psoriasis
treatment. The MCID estimations in psoriasis patients of the PCS and
MCS of the SF-36 varied between 0.5–3.9 and 1.8–6.61 points,
respectively. In contrast to the DLQI, the SF-36 detected gender
differences in patients with hand eczema (Wallenhammar et al.,
2004). Internal consistency of the SF-36 has not been reported in
patients with skin diseases.
The SF-12 was developed from the SF-36 for use in large surveys
and longitudinal studies and includes seven items PCS items and five
MCS items with 2–6 response options (Ware et al., 1995, 1996).
Table 2. Short global evaluations of the HRQOL instruments
HROQL
instrument Short global evaluation
SF-36 Although its structure and retest reliability may be somewhat controversial, the SF-36 is the most studied and validated HRQOL instrument
available and behaves well in a broad range of clinical conditions. The SF-36 is considered the reference instrument by most researchers.
SIP This is a long tool of 136 items and is not an optimal instrument in dermatology because of its focus on disability, which is likely to result
in skewed response distributions and unresponsiveness to change.
NHP The binary item responses of NHP make it an easy to administer HRQOL instrument but this may affect the instruments’ response
distribution and responsiveness. Additional research of NHP behavior in dermatology patients is warranted.
WHOQOL This is promising new instrument to assess overall QOL and is truly cross culturally equivalent. Additional research is needed and
supposedly ongoing to test the long and short version of the WHOQOL tool, in and outside dermatology.
DLQI This instrument was the first and is the most widely used dermatology-specific HRQOL instrument, but has several major limitations such
as focus on disability, response distribution, and dimensionality and item bias.
Skindex The Skindex-29 is a valid, reliable and responsive instrument. For now, we recommend its use, but its current scales did not fit the Rasch
model (questioning its structure) and the meaning of the scores is not well documented. Of the reduced versions, the Skindex-16 is likely
to have similar (dis)advantages and the Skindex-17 is promising because it fitted both the classical test and item response theory, but
additional validation studies are needed.
DQOLS The development of this tool has been suboptimal with regard to item creation and selection. Some of the psychometric techniques used
are unusual.
DSQL The initial item creation and selection has been suboptimal. Validation was restricted to acne and/or contact dermatitis patients. The items
responses are heterogeneous and summing of the overall score is inappropriate.
DLQI, Dermatology Life Questionnaire Index; DSQL, Dermatology-Specific Quality of Life; DQOLS, Dermatology Quality of Life Scales; HRQOL, health-
related quality of life; NHP, Nottingham Health Profile; SF-36, Short-Form-36; SIP, Sickness Impact Profile; WHOQOL, World Health Organization Quality
of Life.
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Table 3. Important characteristics of HRQOL instruments1
Characteristics Definitions Grades and criteria
Validity
Conceptual2
Construct3
Convergent3
Does the tool measure what it is supposed
to measure?
Are the relevant domains captured?
Does tool confirm hypothesized difference
(e.g., diagnosis, clinical disease severity,
others)
Does the tool relate to other tools
measuring the same construct?
A1: well balanced
objective and
subjective
domains
B1: more focused
on objective or
subjective
domains
C1: missing
important HRQOL
domains.
A2:475% of
results are in
accordance with
specific
hypotheses
B2: o75 of results
are in accordance
with specific
hypotheses
C2: no
information.
A3: correlation40.70
B3: correlationo0.70
C3: no information
Interpretability
Norms
Categorization
MCID4
Are there standard comparative data from
the general population and/or dermatology
patients published and/or available?
Are there categories of the obtained score
available?
Has the minimal change that is relevant to
patients been reported?
A1: general and
dermatology
patients
B1: general or
dermatology
patients
C1: general nor
dermatology
patients
A2: using anchor
or banding
techniques
B2: using
distribution based
techniques
C2: not reported
A3: MCID is known in
heterogeneous sample
B3: MCID is known in
limited sample
C3: not reported
Dermatology patients
For generic tools
Testing
For dermatology-
specific tools
Development
Testing
Has the instrument been validated in
dermatology patients?
Have patients with a variety skin diseases
been involved in the development of the
tool?
Has the tool been used in a variety skin
diseases?5
A1: yes, tested for validation, reliability and responsiveness
B1: yes, tested for validation, reliability and/or responsiveness
C1: not at all
A2–3: large
B2–3: moderate
C2–3: little
Floor and ceiling
effects (measurement
model)
Does the tool capture the detail and
breadth of real differences among persons?
(i.e., does the tool or its scales show ‘floor’
or ‘ceiling’ effects of 420%?)
A: no problems
B: some problems
C: substantial problems
Reliability3,6
Internal consistency
Retest-reliability Does the tool provide a consistent answer?
The extents to which items in a (sub)scale
are intercorrelated, thus measuring the
same construct (Cronbach’s a)?
Does a repeated administration of the tool
within a reasonable period result in a
similar outcome?
A1: 0.954Cronbach’s a40.70
B1: Cronbach’s ao 0.7 or 40.95
C1: Cronbach’s a not reported
A2: k or ICC 40.7
B2: k or ICC o0.7 or
correlation
coefficients40.7
C2: k or ICC not
reported or
correlation
coefficiento0.7
Structure Have the domains and/or summary score
of the tool been confirmed?
A: item response theory
B: Factor analysis
C: no factor analysis or item response theory.
Responsiveness Is the tool sensitive to detect changes over
time or due to therapy using patient
centered and/or clinical criteria?
A: strong
B: moderate or conflicting evidence
C: absent, weak, or solely based on statistical evidence
Item bias Do the items of the tool function similar
across external factors such as age, gender
and diagnosis?
A: strong
B: moderate or conflicting evidence
C: absent or weak
Cultural issues
Translations
Cultural
equivalence
Has the tool been translated using
guidelines?
Has the tool been analyzed in a cultural
equivalence study?
A1: always
B1: sometimes
C1: never, not reported
A2: always
B2: sometimes
C2: never
Respondent burden Is the length and content acceptable to the
patients?
A: brief (o15 min)
B: long or problems of acceptability
C: long and problems of acceptability
Table 3 continued on follow page
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Table 3. continued
Characteristics Definitions Grades and criteria
Administrative burden How easy is the tool to administer, score
and interpret (i.e., is specialized training or
special software required)?
A: simple
B: moderate
C: complex
Alternative forms Is the tool available and tested for alternate
forms of administration such as interviews
in person or telephone, self-administration
or computer-assisted interviews.
A: strong evidence
B: moderate or conflicting evidence
C: absent or weak evidence
HRQOL, health-related quality of life; ICC, intraclass correlation coefficient.
1Adjusted from Lohr et al. (1996); Andresen (2000) and Terwee et al. (2007).
2Objective and subjective domains are described by Muldoon et al. (1998).
3Criteria of construct validity and reliability were based on description by Terwee et al. (2007).
4MCID, minimal clinically important difference (i.e., the minimal difference, which is measured and is relevant to a patient and is not due to intrinsic
variance of the instrument).
5Refer to Table 2.
6Reliability is concerned with the temporal stability of instrument scores (test-retest) and internal consistency, which is estimated by Cronbach’s a, evaluates
the relationship between all items (of a scale) and their ability to measure a single underlying domain. Test–retest reliability assess score consistency over two
points in time assuming no change in health status and may provide a more rigorous of reliability due to the different sources of variance. Test–retest
reliability should best be expressed in a k coefficient or ICC. Spearman’s correlation coefficients are less optimal for retest reliability. No distinction was
made for comparisons at group or person level.
Table 4. Generic and dermatology-specific HRQOL instruments including their health domains
Generic HRQOL
instruments
(health profiles) SF-361 NPH SIP WHOQOL
Physical functioning
Role limitations due to
physical problem
Bodily pain
General health
Vitality
Social functioning
Role limitations due to
emotions
Mental health
Health transition
Energy level
Emotional reactions
Physical mobility
Pain
Social isolation
Sleep
Physical dimension
Ambulation
Mobility
Body care and movement
Psychosocial dimension
Communication
Alertness behavior
Emotional behavior
Social interaction
Independent categories
Sleep and rest
Eating
Work
Home management
Recreation and pastimes
Physical
Psychological
Level of independence2
Social relationships
Environment
Spirituality2
Dermatology-specific
HRQOL instruments
DLQI
Symptoms
Daily activities
Leisure
Work/school
Personal relationships
Treatment
Skindex3
Emotions
Functioning
Symptoms
DQOLS
Psychosocial
Embarrassment
Despair
Irritableness
Distress
Activities
Everyday
Summer
Social
Sexual
Symptoms
DSQL
Physical symptoms
Daily activities
Social activities
Work/school experiences
Self-perception
SF-36 vitality subscale
SF-36 mental subscale
DLQI, Dermatology Life Questionnaire Index; DQOLS, Dermatology Quality of Life Scales; DSQL, Dermatology-Specific Quality of Life; HRQOL, health-
related quality of life; NHP, Nottingham Health Profile; SF-36, Short-Form-36; SIP, Sickness Impact Profile; WHOQOL, World Health Organization Quality
of Life.
1SF-36 includes eight scales and has a physical and mental component. The SF-12 includes the later two components.
2Conceptually, the WHOQOL has six domains but two could not be confirmed by factor analysis.
3The Skindex-29 and-16 have three domains but the psychosocial scale of the Skindex-17 combines emotions and functioning resulting in two domains.
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Although the SF-12 explained more than 90% of the SF-36
variance and validation studies including factor analysis
confirmed its structure and good psychometric characteristics
(Jenkinson and Layte, 1997), it is considered a less valid,
reliable, and responsive instrument compared to the SF-36
(Haywood et al., 2005). In heart failure patients, the MCID of the
SF-12 PCS and MCS was 1.3 and 2.3 points, respectively (Bennett
et al., 2003). The SF-12 has been tested for cultural equivalence
across nine countries (Gandek et al., 1998). It takes less than
5 minutes to administer the single page SF-12, which can be
scanned, and alternative forms such as computer administration
exist. The SF-12 has been used in a French general population survey
to assess the impact of sensitive skin (Misery et al., 2005), a
comparative study of HRQOL instruments in patients with venous
leg ulcers (Iglesias et al., 2005) and in the validation of a utility
questionnaire in patients with skin cancers (Littenberg et al., 2003).
No psychometric evaluation of this tool has been reported in
dermatology patients.
Sickness impact profile. The Sickness Impact Profile (SIP) was
one of the first self-reported health measures published in 1976
and revised in 1981 (Bergner et al., 1981). The SIP focuses on
the objectively measurable impact of illness on daily activities
and behaviors and much less on the mental aspects of diseases.
It contains 136 items divided over 12 scales (Table 4). Apart
from five independent scales, these scales can be grouped into a
physical (four scales) and psychosocial domain (three scales).
The SIP does not include a pain scale. The construct validity
of the SIP judged by factor analysis has not been documented
(De Bruin et al., 1992). The SIP asks a respondent to tick only
the items that are applicable to him on a given day. This speeds
up the administration, but complicates the interpretation of
missing items (i.e., was the activity not applicable on a given day
or is the item mistakenly missed?) The items are weighted based on
the level of dysfunction the item represents. The scores obtained
(range 0–100) can be calculated per scale, domain, and as an overall
score (most often used), but their interpretability is not well
Table 5. The different skin conditions in which the HRQOL instruments have been used
HRQOL
instruments Used in following skin conditions
SF-36 Acne1, atopic, contact and occupational dermatitis25, herpes zoster6, ichthyosis7, lupus erythematosus8, neurofibromatosis9,
(non)melanoma skin cancer1,10,11, port wine stains12, psoriasis2,13, sensitive skin1,14, Sezary syndrome15, systemic sclerosis16, toxic
epidermal necrolysis17, ulcers1,18, varicose veins19
SIP Atopic dermatitis20, basal cell carcinoma21, Ehlers–Danlos syndrome22, psoriasis13
NHP chronic (pressure) urticaria23,24, eczema25, ichtyosis26, leg ulcers27, lymphedema28, psoriasis13
WHOQOL-100 Melasma2,29, psoriasis30, sarcoidosis31
DLQI acne (ectopica)35, actinic keratosis35, alopecia35, atopic dermatitis35, basal cell carcinoma35, Behcet‘s disease35, bullous pemphigoid35,
contact dermatitis35, Darier‘s disease35, discoid lupus erythematosus35, dystrophic epidermolysis bullosa35, erythropoietic
protoporphyria36, Haily-Haily disease35, hirsutism35, HIV lipodystrophy37, hyperhidrosis35, ichtyosis7, leg ulcers35, lichen planus35,
lymphoedema35, melasma35, nevi35, nonmelanoma skin cancer11, prurigo35, pityriasis rosea35, pruritis35, psoriasis13,35, radiation
dermatitis38, rosacea35, scabies35, seborrheic dermatitis35, seborrheic warts35, tinea35, warts35.
Skindex-29 Acne39,40, actinic keratosis39, alopecia39,41, atopic dermatitis42, benign growths39, cutaneous T-cell lymphoma43, fungal disease39, hand
dermatitis44, Haily–Haily disease45, HIV-related dermatoses46, hyperhidrosis47, leg ulcers48, nail disease39, neurofibromatosis-149, nevi50,
onychomycosis50, psoriasis13, rosacea39, scalp dermatitis51, skin cancer39, ulcer39, viral disease39, vitiligo39
Skindex-16 Acne52, actinic keratosis53, atopic and contact dermatitis54,55, benign tumors53, chronic venous insufficiency56, dermatomyositis57, facial
blemishes58, seborrheic dermatitis53, nonmelanoma skin cancer59, melasma60, warts53
Skindex-17 Acne61, alopecia areata61, nevi61, psoriasis61, seborrheic dermatitis61, vitiligo61
DSQL Acne62, contact dermatitis62
DQOLS Acne64, eczema64, psoriasis65, urticaria66
DLQI, Dermatology Life Questionnaire Index; DQOLS, Dermatology Quality of Life Scales; DSQL, Dermatology-Specific Quality of Life; HRQOL, health-
related quality of life; NHP, Nottingham Health Profile; SF-36, Short-Form-36; SIP, Sickness Impact Profile; WHOQOL, World Health Organization Quality
of Life.
1Also, used SF-12.
2Used WHOQOL-BREF.
References: (1) Klassen et al. (2000); (2) Lundberg et al. (2000); (3) Thomson et al. (2002); (4) Wallenhammar et al. (2004); (5) Hutchings et al. (2001); (6)
Chidiac et al. (2001); (7) Ganemo et al. (2004); (8) Ferraz et al. (2006); (9) Wolkenstein et al. (2001); (10) Trask and Griffith (2004); (11) Rhee et al. (2003);
(12) Schiffner et al. (2002); (13) de Korte et al. (2002); (14) Misery et al. (2005); (15) Bouwhuis et al. (2003); (16) Cossutta et al. (2002); (17) Haber et al.
(2005); (18) Iglesias et al. (2005); (19) Chetter et al. (2006); (20) Salek et al. (1993); (21) Blackford et al. (1996); (22) Berglund and Nordstrom (2001); (23)
Berrino et al. (2006); (24) O’Donnell et al. (1997); (25) Whalley et al. (2004); (26) Ganemo et al. (2004); (27) Lindholm et al. (1993); (28) Sitzia and Sobrido
(1997); (29) Cestari et al. (2006); (30) Skevington et al. (2006); (31) Guryleva (2003); (32) Kernick et al. (2000); (33) Shikiar et al. (2006); (34) Weiss et al.
(2005); (35) Lewis and Finlay (2004); (36) Holme et al. (2006); (37) Blanch et al. (2004); (38) Wells et al. (2004); (39) Sampogna et al. (2004b); (40) Lasek and
Chren (1998); (41) Fischer et al. (2001); (42) Augustin et al. (2004); (43) Demierre et al. (2005); (44) Fowler et al. (2006); (45) Gisondi et al. (2005); (46)
Mirmirani et al. (2002); (47) Weber et al. (2005); (48) Hareendran et al. (2005); (49) Page et al. (2006); (50) Zghal et al. (2003); (51) Chen et al. (2002); (52)
Hayashi et al. (2005); (53) Chren et al. (2001); (54) Higaki et al. (2004); (55) Kadyk et al. (2003); (56) Duque et al. (2005); (57) Hundley et al. (2006); (58)
Balkrishnan et al. (2006); (59) O’Reilly et al. (2006); (60) Balkrishnan et al. (2003); (61) Nijsten et al. (2006b); (62) Anderson and Rajagopalan (1998); (63)
Anderson and Rajagopalan (1997); (64) Morgan et al. (1997); (65) Feldman et al. (2004); (66) O’Donnell et al. (1997).
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documented. However, of the 136 items that sum up to the
overall score, only 82 items fitted an extended Rasch model
suggesting that an overall score is not appropriate (Lindeboom
et al., 2004). The SIP has been reported as a valid and reliable
tool (de Bruin et al., 1992; Coons et al., 2000) with some
important limitations (Tables 1 and 2). The SIP works best in patient
groups with moderate to high disability associated with mobility
impairment (e.g., psoriasis patients with arthritis). The SIP suffers
from ceiling effects in general population samples, suggesting that it
is insensitive to change in these circumstances and does not
discriminate well among relatively healthy individuals (Andresen
and Meyers, 2000). Twenty-three items showed significant item bias
across age, gender, and diagnosis (Lindeboom et al., 2004).
Depending on the patients’ health, it takes about 30 minutes to
complete the SIP and it can be self-administered. The SIP has been
translated into several languages using varying methods that seem to
function well, but cross-cultural equivalence studies are lacking
(Anderson et al., 1996).
The SIP has been used in psoriasis research (Table 5) to assess the
effect of cyclosporin, in and outpatient dithranol and calcipotriol
therapy (Wall et al., 1998; de Korte et al., 2002; Prins et al., 2005).
Despite its insensitivity in patients with low levels of impairment and
its focus on disability, the SIP has been used to assess the impact of
basal-cell carcinoma (Blackford et al., 1996). No psychometric
evaluation of the SIP has been reported in dermatology, except in a
small validation study of the Psoriasis Disability Index (Finlay et al.,
1990).
Nottingham Health Profile. The Nottingham Health Profile
(NHP) was developed as a survey tool to reflect the lay perception
of health status in the United Kingdom (Hunt et al., 1986;
McEwen and McKenna, 1996). The NHP assesses subjective
health with binary responses (‘‘yes/no’’) to 38 items in six sections
(Table 4). The social domain is underrepresented in the NHP,
but it includes sleep (Essink-Bot et al., 1997). The NHP results
can be analyzed by summing the number of positive responses
in a dimension or weighting items to calculate a dimension
score (range 0–100). A factor analysis yielded two higher order
factors confirming the two domains of the NHP (Essink-Bot et al.,
1997), but this structure could not been confirmed by Rasch analysis
(Prieto et al., 1998). Only a few reliability studies of the NHP
have been performed and suggested a good test–retest reliability
and a moderate Cronbach’s a of about 0.7 (Coons et al., 2000).
The simple NHP scoring format has the advantage that missing
values are low and it can be completed swiftly (5–10 minutes).
However, if individuals score ‘‘yes’’ (i.e., the problem is present) and
they get worse they cannot express this deterioration. Indeed, the
NHP has been reported to be not very sensitive to minor levels of
impairment and change over time (Table 2). For example, 26% of
patients with acne or psoriasis who visited an UK outpatient
university hospital clinic scored optimal on all NHP categories
(Morgan et al., 1997). Limited normative data of the general
population are available (Erdman et al., 1993). The NHP is intended
for self-administration, but can also be administered by an interviewer.
In a review about cultural equivalence, the authors conclude that there
is preliminary evidence that the basic properties of multiple NHP
versions, which have been unauthorized and untested, have been
retained (Anderson et al., 1996).
The NHP has been used in validation studies of patients
with eczema and psoriasis and correlated poorly with the DLQI
(ro0.32), but the ‘‘emotional reactions’’ and ‘‘mobility’’ domains
were more responsive than some of the DLQI domains (Badia et al.,
1999). It has been used to test the convergent validity of the
Dermatology-Specific Quality of Life (DSQL; Morgan et al., 1997).
Several cross-sectional studies have used the NHP to assess HRQOL
in dermatological patients (Table 5), but no studies have been
published that included its reliability, factor analysis, responsiveness
and item functioning.
WHOQOL. In 1998, the WHOQOL-100, which was designed
prospectively in 15 health centers worldwide, was published
(WHOQOL Group, 1994, 1998a). From an initial pool of 1,800
questions and a pilot study of 236 items, 100 items (plus four global
items) were selected using strict quantative and qualitative criteria.
The items refer to the prior 2 weeks and use a five-point response
scale. Conceptually, 24 ‘‘facets’’ with each four items and four
general questions (total is 100 items) were grouped in six domains
(Table 4), but factor analyses retained only four domains (WHOQOL
Group, 1998a). The WHOQOL assess overall QOL and not just
HRQOL: it includes domains such as ‘‘environment’’ and ‘‘spiri-
tuality’’. More than half of the variance of the 24 facets was
explained by ‘‘positive feelings’’ suggesting that this is an important
predictor of an individuals overall QOL (Skevington, 1999).
Although there is a WHOQOL Rasch Project Scientific Committee,
no Rasch analysis has yet been published. In populations from the
UK and USA, the WHOQOL demonstrated to have good discrimi-
nant validity, reliability (Cronbach’s a values and intraclass
correlation coefficients 40.80) and responsiveness (Table 1; Ske-
vington, 1999; Bonomi et al., 2000). The convergent validity of the
WHOQOL was not optimal because it did not consistently correlate
with SF-36 as expected (Bonomi et al., 2000). The interpretability of
the obtained scores is not documented, except one study reporting
normative data for the general Danish population (Noerholm et al.,
2004). The burden for the respondent is substantial given the high
number of items, but the administrative burden for the researcher is
relatively low given the ease of the scoring algorithm. Each of the
over 40 translations has been performed in accordance with a strict
protocol. Remarkably, none of the initial ‘‘national’’ questions had to
be included in the final WHOQOL-100, which makes it a truly
cross-cultural instrument.
The WHOQOL-100 has been extensively investigated in
psoriasis patients treated in an Ingram regimen outpatient program
(Skevington et al., 2006). Apart from the social and environment, all
domains were significantly more affected among psoriasis patients
compared to healthy individuals. More severe disease correlated
negatively with physical health and level of independence but not
with the other QOL domains. Convergent validity was generally
supported by modest to good correlations with the SF-36. All items
showed a Cronbach’s a of 0.95 and for most domains it was 40.80.
The Ingram regimen improved four of six domains suggesting an
adequate responsiveness.
In 1998, a short form of the WHOQOL-100 instrument
(i.e., WHOQOL-BREF) was developed for brief QOL assess-
ments in epidemiological surveys and/or clinical trials (WHOQOL
Group, 1998b; http://www.who.int/substance_abuse/research_tools/
whoqolbref/en/). Conceptually, the WHOQOL work group
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decided that at least one item of each of the 24 facets
should remain in the short version. In a large group of patients from
18 different countries, 26 items were selected based on four
criteria including variance explained, confirmatory factor
analyses, and discriminate validity. The four domains of the original
and brief version correlated well, showed good to excellent internal
consistency, and good retest reliability. Each of the four domains of
the WHOQOL-BREF fitted a two-parameter IRT model but did not
fit the Rasch model suggesting that domains scores are more
appropriate than a composite score (Noerholm et al., 2004). The
WHOQOL-BREF has been used in patients with (cutaneous)
sarcoidosis and in the validation of a melasma-specific HRQOL
tool (Table 5). It has not been psychometrically tested in
dermatology patients.
Dermatology-specific HRQOL instruments
DLQI. The DLQI was the first dermatology-specific tool to assess
skin-related QOL. It was designed as ‘‘a simple practical measure for
routine clinical practice’’ (Finlay and Khan, 1994; http://www.der-
matology.org.uk/). This instrument was developed in UK patients
visiting a university clinic and focused on patients’ functioning in
their daily activities and does not fully capture emotions and mental
health (Badia et al., 1999; De Korte et al., 2002). This suggests that
the DLQI may lack conceptual validity in patients with minor
dermatological conditions or in diseases primarily affecting mental
health such as vitiligo and alopecia. The measure has 10 items rated
on a four-point scale. However, the response format has been
dichotomized because of numeric instability in patients with hand
eczema (Wallenhammar et al., 2004) and patients were unable to
differentiate between response categories for most items (Nijsten
et al., 2006a, 2007). A composite score can be calculated (range
0–30). In psoriasis patients, a confirmatory factor analysis showed a
clear second-order factor structure suggesting the underlying
unidimensionality of the DLQI, but this could not be confirmed by
several Rasch analyses (McKenna et al., 2004; Mazzotti et al., 2005;
Nijsten et al., 2006a, 2007). On the basis of face validity the
developers of the DLQI suggested that six health domains (Table 4)
were assessed, but subsequent factor analyses did not confirm this
assumption (Kent and Al-Abadie, 1996; Wallenhammar et al.,
2004; Mazzotti et al., 2005). The internal consistency is good to
excellent. For test–retest reliability, high Spearman’s correlation
coefficients were reported (Table 1; Lewis and Finlay, 2004).
Correlations between DLQI and other HRQOL measures were
high and in the expected direction, except that the DLQI correlated
less with mental and emotional aspects. The DLQI has been
proven to be responsive to change, but may not be very sensitive
to detect small impairments because of substantial ceiling
effect. Items 1 and 2 account for most of the DLQI’s variability
(Morgan et al., 1997; Badia et al., 1999; Shikiar et al., 2006).
Five categories of the DLQI scores have been proposed (Hongbo
et al., 2005). The MCID of the DLQI varied between 3 and 6
points in patients with chronic urticaria and psoriasis (Shikiar et al.,
2005, 2006). A large proportion of the items behaved significantly
different across gender and age (Nijsten et al., 2006a, 2007). No
information is available whether the items of the DLQI function
comparable in patients with different skin diseases. It takes less
than 5 minutes to complete. Different administration forms are
available including an illustrated, family and children’s version
(http://www.dermatology.org.uk). Multiple translations have been
used, but little documentation is published on the translation
process, except for the more recent ones. A recent cultural
equivalence study in psoriasis patients suggest that the scoring of
all items were affected by nationality (Nijsten et al., 2007). By now,
the DLQI is the most commonly used HRQOL instruments in
dermatology and is used in most HRQOL studies in patients with
skin diseases (Table 5; Lewis and Finlay, 2004).
Skindex. The Skindex-29 was designed to measure HRQOL in
different populations and to detect changes in time Chren et al.,
1996, 1997a, b). Its development study included patients from US
private practices and a Veteran hospital. The first Skindex consisted
of 61 items, but a refinement study resulted in the Skindex-29. The
Skindex-29 has 30 items of which 29 items (except item 18) are
assigned to three scales with separate scores (Table 4). This structure
has been confirmed in several factor analyses (Chren et al., 1997b;
Abeni et al., 2002; Augustin et al., 2004). Although a composite
score is sometimes calculated, it has not formerly been studied, has
no face validity and did not fit the Rasch model (Nijsten et al.,
2006b). The questions ask about frequency respondents experience
the assessed impact on their life on a five-point response scale.
Distribution-based analyses suggested that there are four to five
categories for the three Skindex-29 scales (Nijsten et al., submitted).
The Skindex-29 scored well for most criteria, except interpretability
of scores, structure, and item bias (Table 1). Several items show item
bias across gender, age, disease severity, and diagnosis (Nijsten
et al., 2006b). Completion requires about 10 minutes. In The
Netherlands, a computerized version is available. The Skindex-29
has been translated from US English into Dutch, German, Spanish,
Italian using a standard protocol, but about half the items of the 29
show differential item functioning across culture (Nijsten et al.,
2007). The development studies of the Skindex-29 and the validation
studies of the German, Italian, and Spanish translations were
performed in large, heterogeneous patient populations (Chren
et al., 1996; Jones-Caballero et al., 2000; Abeni et al., 2002;
Augustin et al., 2004). The Skindex-29 has been predominantly used
in independent cross-sectional studies in a variety of skin conditions
(Table 5) but not in (industry sponsored) clinical trials. Nevertheless,
in a review about the HRQOL instruments in psoriasis, this tool was
considered the measure of choice (de Korte et al., 2002). The
Skindex-29 has been used to test the validity of other (disease-
specific) HRQOL instrument such as the Scalpdex (Chen et al.,
2002), pictorial presentation of illness measure in vitiligo (Rumpf
et al., 2004) and Skindex-17.
Two brief versions of the Skindex-29 exist. First, the Skindex-16
included items of the Skindex-29 that were not mentioned in
qualitative responses to open-ended questions and/or more than half
the participants responded ‘‘never’’ were deleted (Chren et al.,
2001). The three original scales of the Skindex-29 were respected. In
addition to reducing the number of items, the Skindex-16 assesses
degree of ‘‘bother’’ and not ‘‘frequency’’ and some items were
refined or collapsed. In the development study of the Skindex-16 its
three scales showed good to excellent internal consistency, good
content, and construct validity and were responsive (Table 2). These
psychometric characteristics were confirmed in a validation study of
a Japanese version of the Skindex-16 and in atopic dermatitis (Higaki
et al., 2002, 2004). Since it was published in 2001, the Skindex-16
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has been used in several skin conditions (Table 5) and in the
validation of melasma-specific HRQOL instrument (Balkrishnan
et al., 2003).
Second, the Skindex-17 is a Rasch reduced version of the
Skindex-29 (Nijsten et al., 2006b). It has a psychosocial and a
symptom scale. The five-point scoring system was re-grouped
into three categories and demonstrated logical response order
for all but one item. More than 85% of the variance of the
three Skindex-29 scales was captured by the two scales of the
Skindex-17 suggesting that little information was lost. No item
bias was detected across gender, age, disease severity, and six
diagnoses. Classical psychometric properties such as response
distribution and internal consistency of the two subscales of the
Skindex-17 were adequate (Table 2). The majority of the items of the
psychosocial but not of the symptom scale were cultural equivalent
(Nijsten et al., 2007). A validation study of the Skindex-17 in
psoriasis patients from other European countries confirmed its good
psychometric properties (Nijsten et al., 2007). So far, the Skindex-17
has only been studied and tested using existing data from the
Skindex-29.
Dermatology Quality of Life Scales. Fifty outpatients from an
UK university dermatology department were asked ‘‘to write down
all the ways your skin condition affects you’’ by the subheadings
feelings and personal relationships, daily and social activities and
symptoms (Morgan et al., 1997). Subsequently, the developers
created the Dermatology Quality of Life Scales (DQOLS) yielding 17
psychosocial, 12 physical items, and 12 symptom items. A five-point
response scale was used assessing patients’ current experience. The
three domains have separate scores ranging between 0 and 100. The
questionnaire was validated in a different sample of 118 patients
attending a hospital outpatient clinic (more than half had inflam-
matory skin diseases). Explanatory factor analysis showed four
subscales of the psychosocial and activities scales (Table 4). The
internal consistency was excellent for the psychosocial and activities
scales (0.92 and 0.83, respectively) and the retest reliability was
tested in 50 UV-treated patients (Table 1 and 2). Some of the
techniques in the psychometric evaluation of the DQOLS were
unusual such as the use of different patient samples, a Bland Altman
plot (Bland and Altman, 1986; Gompertz et al., 1992) to estimate
retest reliability and the comparison between Dermatology-Specific
Quality of Life (DSQL) and NHP scores to assess ‘‘sensitivity’’.
Several hypotheses were tested to assess DQOLS construct validity
and its’ face validity was considered good using the DLQI as
reference. It takes 5–10 minutes to complete this instrument. Except
for a cross-sectional study in patients with chronic urticaria and in a
clinical trial of alefacept in psoriasis (Table 5), the use of this
instrument has not been reported in dermatological studies.
DSQL. In 1997, US researchers published the DSQL (Anderson
and Rajagopalan, 1997). In total 52 items were included, which
were derived from the SF-36, the literature, clinical experience,
and a focus group of seven acne patients. Of the 52 items, eight
were global questions scored on a 0–10 scale assessing intensity
or satisfaction and the remaining items on a five-point ordinal
scale assessing frequency. All items asked about the ‘‘last month’’
and grouped into seven scales (Table 4). A summary score was
obtained by simply adding all raw scores. A pilot study to assess
item behavior was restricted to acne patients and the final report
includes patients with contact dermatitis as well. In the DSQL
development study, the psychometric properties were reasonable
and included construct validity, internal consistency, and factor
analysis and, in acne patients, it was responsive (Table 1 and
2)(Anderson and Rajagopalan, 1998). The DSQL is self-administered
and takes less than 15 minutes to complete. Except in subsequent
acne and contact dermatitis studies by the developers of the DSQL
(Table 5), this tool has not been used nor tested in other
dermatological populations.
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